Comparative Pharmacology
Head-to-head clinical analysis: DIONOSIL AQUEOUS versus IOPAMIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIONOSIL AQUEOUS versus IOPAMIDOL.
DIONOSIL AQUEOUS vs IOPAMIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIONOSIL AQUEOUS contains propyliodone, a radiocontrast agent that absorbs X-rays, providing visualization of bronchial structures. It acts by coating the bronchial mucosa and filling the airways, allowing radiographic imaging.
Iopamidol is a nonionic, water-soluble radiographic contrast agent that attenuates X-rays by increasing the density of vascular structures and organs, thereby enhancing contrast in imaging studies. It does not have a pharmacological mechanism of action but exerts its effect via physical radiopacity.
Intra-articular injection: 2-3 mL of 1% solution (20-30 mg) per joint; maximum 4 joints per session. Intravenous: 2-4 mL of 20% solution (400-800 mg) diluted in 20 mL water, administered slowly over 5-10 minutes, for peripheral angiography.
Intravenous or intra-arterial administration; dose varies by procedure (e.g., cerebral angiography: 5-10 mL; coronary arteriography: 3-10 mL per injection; CT: 50-150 mL; adults: up to 200 mL total).
None Documented
None Documented
Clinical Note
moderateIopamidol + Metformin
"The risk or severity of adverse effects can be increased when Iopamidol is combined with Metformin."
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged in renal impairment.
2 hours; prolonged in renal impairment (up to 30 hours in anuria)
Renal excretion of unchanged drug accounts for >95% of elimination; <5% is eliminated via biliary/fecal routes.
Renal: >90% unchanged; biliary/fecal: <2%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent